RT Journal Article
SR Electronic
T1 EVEREST Trial 2-Year Results Show Stability of Percutaneous MV Repair between Years 1 and 2
JF MD Conference Express
YR 2011
FD SAGE Publications
VO 11
IS 3
SP 17
OP 18
DO 10.1177/155989771103009
UL http://mdc.sagepub.com/content/11/3/17.abstract
AB The 2-year results from the Endovascular Valve Edge-to-Edge Repair trial [EVEREST II; NCT00209274] showed that percutaneous mitral valve repair is safe and durable with measurable clinical benefits and is a therapeutic option for select patients with significant mitral regurgitation [Feldman T et al. N Engl J Med 2011].